Wall Street brokerages expect Amneal Pharmaceuticals Inc (NYSE:AMRX) to announce $445.81 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Amneal Pharmaceuticals’ earnings, with the highest sales estimate coming in at $468.50 million and the lowest estimate coming in at $407.10 million. The firm is scheduled to report its next earnings report before the market opens on Thursday, May 9th.
According to Zacks, analysts expect that Amneal Pharmaceuticals will report full-year sales of $1.89 billion for the current fiscal year, with estimates ranging from $1.81 billion to $1.98 billion. For the next financial year, analysts forecast that the firm will report sales of $1.96 billion, with estimates ranging from $1.86 billion to $2.01 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Amneal Pharmaceuticals.
Amneal Pharmaceuticals (NYSE:AMRX) last released its earnings results on Thursday, February 28th. The company reported $0.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.06. The firm had revenue of $497.53 million for the quarter, compared to the consensus estimate of $478.06 million. Amneal Pharmaceuticals had a return on equity of 25.73% and a net margin of 1.84%.
In other Amneal Pharmaceuticals news, Director Peter R. Terreri sold 23,345 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $12.39, for a total transaction of $289,244.55. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Paul Bisaro purchased 17,000 shares of the stock in a transaction dated Tuesday, March 12th. The shares were purchased at an average price of $11.97 per share, for a total transaction of $203,490.00. The disclosure for this purchase can be found here. 26.34% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. FMR LLC increased its holdings in Amneal Pharmaceuticals by 26.4% during the 3rd quarter. FMR LLC now owns 10,039,109 shares of the company’s stock worth $222,767,000 after purchasing an additional 2,095,706 shares in the last quarter. Norges Bank acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at $18,243,000. HealthCor Management L.P. acquired a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $22,991,000. Point72 Asset Management L.P. acquired a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $17,752,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Amneal Pharmaceuticals during the 2nd quarter valued at $7,668,000. Institutional investors own 38.90% of the company’s stock.
Shares of NYSE AMRX traded down $0.30 during mid-day trading on Thursday, hitting $13.42. The company had a trading volume of 394,487 shares, compared to its average volume of 953,434. The company has a market cap of $4.08 billion, a price-to-earnings ratio of 14.13, a price-to-earnings-growth ratio of 0.62 and a beta of 1.38. Amneal Pharmaceuticals has a 12 month low of $11.63 and a 12 month high of $24.48. The company has a current ratio of 2.32, a quick ratio of 1.50 and a debt-to-equity ratio of 2.98.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Further Reading: Call Option Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.